pyrazines has been researched along with Critical Illness in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 14 (87.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chinnairusan, M; Dhanasekaran, S; Kagithakara Vajravelu, L | 1 |
| Ahmed, GY; Al-Jamea, LH; Alhumaid, S; Almahmoud, S; Barry, M; Dhama, K; Khan, A; Layqah, L; Mohaini, MA; Mutair, AA; Rabaan, AA; Shamou, J; Thoyaja, K; Woodman, A | 1 |
| Cheung, J; Gupta, A; Han, D; Majewski, M; Mann, J; Munugalavadla, V; Patel, P; Pepin, X; Sharma, S; Sheridan, L; Tomkinson, H; Townsley, D; Ware, JA; Wei, H; Zheng, L | 1 |
| Cao, B; Chen, C; Fan, G; Guo, L; Hayden, FG; Horby, P; Lu, B; Pan, J; Salam, A; Wang, C; Wang, Y; Zheng, J | 1 |
| Martin-Loeches, I; O'Sullivan, S; Rodriguez, A; Torres, A | 1 |
| Eto, M; Fujita, H; Hashida, T; Ikesue, H; Irie, K; Muroi, N; Nakagawa, A; Tamura, R; Tomii, K | 1 |
| Baselga, J; Chung, KK; Collen, J; Desai, JV; Goy, A; Hamdy, A; Izumi, R; Lionakis, MS; Monticelli, MA; Roschewski, M; Rose, K; Roshon, M; Roswarski, J; Sharman, JP; Staudt, LM; Wilson, WH; Wright, GW; Wrzesinski, SH; Zarakas, MA | 1 |
| Doi, K; Hayase, N; Ikeda, M; Morimura, N; Moriya, K | 1 |
| Hifumi, T; Ishimatsu, S; Isokawa, S; Otani, N | 1 |
| Inoue, KI; Sagawa, T; Takano, H | 1 |
| Dauby, N; Konopnicki, D; Roman, A; Van Praet, S; Vanhomwegen, C; Veliziotis, I | 1 |
| Demir, G; Dheir, H; Erdem, AF; Güçlü, E; Kocayiğit, H; Özmen Süner, K; Tomak, Y; Yaylacı, S | 1 |
| Abraham, I; Al-Jedai, A; Alajami, HN; Alali, AH; Alamer, A; Alfaifi, M; AlHassar, F; Alkharji, F; Almulhim, AS; Almutairi, M; Almutairi, W; Alosaimi, B; Alrashed, AA; Alsaeed, A; Baredhwan, AA; Howaidi, J; Mohzari, Y; Sulaiman, T | 1 |
| Fukuoka, S; Imai, T; Kishaba, T; Maeda, A; Nabeya, D; Nagano, H; Narita, M; Shiiki, S; Takakura, S; Yokoyama, S | 1 |
| Favié, LM; Meijer, A; Murk, JL; Nijstad, AL; Sikma, MA; van Maarseveen, EM | 1 |
| Devereux, S; Gupta, S; Mufti, GJ; Pagliuca, A; Schey, S | 1 |
1 review(s) available for pyrazines and Critical Illness
| Article | Year |
|---|---|
Influenza management with new therapies.
Topics: Adrenal Cortex Hormones; Amides; Antiviral Agents; Critical Care; Critical Illness; Dibenzothiepins; Enzyme Inhibitors; Humans; Influenza, Human; Morpholines; Neuraminidase; Oseltamivir; Pyrazines; Pyridines; Pyridones; Pyrimidines; Pyrroles; Respiration, Artificial; Triazines; Zanamivir | 2020 |
2 trial(s) available for pyrazines and Critical Illness
| Article | Year |
|---|---|
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects.
Topics: Adult; Benzamides; Biological Availability; Critical Illness; Cross-Over Studies; Healthy Volunteers; Humans; Proton Pump Inhibitors; Pyrazines; Suspensions | 2022 |
Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19.
Topics: Adult; Aged; Amides; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Intubation, Gastrointestinal; Male; Pandemics; Pneumonia, Viral; Pyrazines; Respiration, Artificial; SARS-CoV-2; Severity of Illness Index; Suspensions; Tablets; Treatment Outcome | 2020 |
13 other study(ies) available for pyrazines and Critical Illness
| Article | Year |
|---|---|
Letter in response to: Alamer A, Alrashed AA, Alfaifi M, et al. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysi
Topics: Amides; COVID-19; Critical Illness; Humans; Propensity Score; Pyrazines; Retrospective Studies; SARS-CoV-2 | 2022 |
Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia.
Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; COVID-19 Vaccines; Critical Illness; Humans; Intensive Care Units; Male; Pyrazines; Retrospective Studies; SARS-CoV-2; Saudi Arabia | 2022 |
Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection.
Topics: Aged; Amides; Antiviral Agents; Critical Illness; Drug Therapy, Combination; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Pyrazines; Retrospective Studies | 2020 |
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Female; Follow-Up Studies; Humans; Inflammation; Interleukin-6; Male; Middle Aged; Monocytes; Pandemics; Pneumonia, Viral; Prospective Studies; Pyrazines; Respiration, Artificial; SARS-CoV-2; Treatment Outcome | 2020 |
Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series.
Topics: Aged; Amides; Benzamidines; Coronavirus Infections; COVID-19 Drug Treatment; Critical Illness; Drug Therapy, Combination; Female; Guanidines; Humans; Male; Middle Aged; Pyrazines; Treatment Outcome | 2020 |
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.
Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Illness; Guanidines; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2 | 2020 |
Preventing the clinical manifestations and disease progression of coronavirus disease using clinically proven protease inhibitors.
Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Critical Illness; Disease Progression; Guanidines; Humans; Pandemics; Pneumonia, Viral; Protease Inhibitors; Pyrazines; SARS-CoV-2 | 2020 |
Tolerability of favipiravir therapy in critically ill patients with COVID-19: A report of four cases.
Topics: Adult; Amides; COVID-19; Critical Illness; Female; Humans; Male; Middle Aged; Pyrazines | 2021 |
Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Combinations; Female; Humans; Intensive Care Units; Length of Stay; Lopinavir; Male; Middle Aged; Mortality; Pyrazines; Ritonavir; SARS-CoV-2; Treatment Outcome; Turkey | 2021 |
Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis.
Topics: Amides; Antiviral Agents; COVID-19; Critical Illness; Humans; Propensity Score; Pyrazines; Respiration, Artificial; Retrospective Studies; SARS-CoV-2; Saudi Arabia; Sensitivity and Specificity | 2021 |
A case report of super responder of critical COVID-19 pneumonia.
Topics: Aged; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Therapy, Combination; Glucocorticoids; Humans; Lung; Male; Methylprednisolone; Pneumonia, Viral; Pyrazines; Receptors, Interleukin-6; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza.
Topics: Amides; Antiviral Agents; Critical Illness; Fatal Outcome; Hemofiltration; Humans; Influenza, Human; Intensive Care Units; Male; Middle Aged; Netherlands; Oseltamivir; Pyrazines; Tertiary Care Centers | 2018 |
Life-threatening motor neurotoxicity in association with bortezomib.
Topics: Aged; Boronic Acids; Bortezomib; Critical Illness; Female; Humans; Middle Aged; Multiple Myeloma; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Pyrazines | 2006 |